Samjo Management LLC Takes $5.97 Million Position in NeoGenomics, Inc. $NEO

Key Points

• Samjo Management LLC purchased 629,080 shares of NeoGenomics, Inc. for approximately $5.97 million, making it the firm's 11th largest holding.
• Several institutional investors, including Allspring Global Investments and GAMMA Investing LLC, significantly altered their positions in NeoGenomics during the 1st quarter, indicating a growing interest in the stock.
• Analysts have set a consensus price target of $12.75 for NeoGenomics, with the company receiving a mix of ratings, including four "buy" and eight "hold" ratings.

Samjo Management LLC bought a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 629,080 shares of the medical research company's stock, valued at approximately $5,970,000. NeoGenomics comprises 2.5% of Samjo Management LLC's portfolio, making the stock its 11th largest position. Samjo Management LLC owned 0.49% of NeoGenomics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its holdings in shares of NeoGenomics by 54.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 33,461 shares of the medical research company's stock worth $318,000 after purchasing an additional 11,733 shares during the period. GAMMA Investing LLC increased its holdings in shares of NeoGenomics by 1,107.7% during the 1st quarter. GAMMA Investing LLC now owns 17,765 shares of the medical research company's stock worth $1,872,000 after purchasing an additional 16,294 shares during the period. Squarepoint Ops LLC bought a new position in shares of NeoGenomics during the 4th quarter worth about $276,000. Northern Trust Corp increased its holdings in shares of NeoGenomics by 7.4% during the 4th quarter. Northern Trust Corp now owns 1,621,809 shares of the medical research company's stock worth $26,727,000 after purchasing an additional 111,170 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of NeoGenomics by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,436,858 shares of the medical research company's stock worth $56,645,000 after purchasing an additional 78,211 shares during the period. Institutional investors own 98.50% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. BTIG Research restated a "neutral" rating on shares of NeoGenomics in a report on Wednesday, July 30th. Needham & Company LLC reduced their price target on shares of NeoGenomics from $8.50 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday, July 29th. Leerink Partners lowered shares of NeoGenomics from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $25.00 to $9.00 in a research report on Wednesday, April 30th. The Goldman Sachs Group reduced their target price on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Finally, William Blair restated a "market perform" rating on shares of NeoGenomics in a report on Tuesday, July 29th. Four analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $12.75.

NeoGenomics Stock Up 0.4%

NeoGenomics stock traded up $0.03 during mid-day trading on Thursday, reaching $7.11. The company's stock had a trading volume of 911,320 shares, compared to its average volume of 1,935,071. The company has a market capitalization of $917.82 million, a price-to-earnings ratio of -8.77 and a beta of 1.54. NeoGenomics, Inc. has a 12 month low of $4.72 and a 12 month high of $19.11. The business's 50 day simple moving average is $6.55 and its 200 day simple moving average is $8.29. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.58 and a current ratio of 3.92.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.